NCT06164730View on ClinicalTrials.gov

A Study of VERVE-102 in Patients with Familial Hypercholesterolemia or Premature Coronary Artery Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Heterozygous Familial HypercholesterolemiaPremature Coronary Heart Disease
Interventions
DRUG

VERVE-102

Intravenous (IV) infusion

Trial Locations (8)

Unknown

RECRUITING

Clinical Study Center, Adelaide

RECRUITING

Clinical Study Center, Melbourne

RECRUITING

Clinical Study Center, Chicoutimi

RECRUITING

Clinical Study Center, Montreal

RECRUITING

Clinical Study Center, Toronto

RECRUITING

Clinical Study Center, Christchurch

RECRUITING

Clinical Study Center, London

RECRUITING

Clinical Study Center, Manchester

All Listed Sponsors
lead

Verve Therapeutics, Inc.

INDUSTRY